Foreign companies must comply with US Medical Device Reporting regulations (MDR)
This article was originally published in Clinica
While the US FDA considers alternative proposals to the US designated agent requirements, foreign manufacturers are responsible directly for complying with the new medical device reporting regulations which came into effect last week. The agency decided to suspend enforcement of the US designated agent and manufacturer certification provisions in June in response to industry concerns (see Clinica No 709, p 7). The agency has proposed revisions to these requirements.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.